Semaglutide vs Tirzepatide Comparison Chart: Doses Side by Side
You are comparing tirzepatide and semaglutide. You see their dose ranges, but the numbers look nothing alike. You wonder if one is “stronger” per milligram. You want to know which one produces more weight loss. The confusion is legitimate, because these medications are fundamentally different compounds acting on different biological pathways. Here is what the dosages actually tell you and how the clinical trials compare.
Why tirzepatide and semaglutide doses look so different
Semaglutide is a GLP-1 receptor agonist. It activates one receptor in the brain and gut that controls appetite and blood sugar. Its usual dose range for weight management is 0.25mg to 2.4mg per week, and the current label allows some adults to increase to a maximum of 7.2mg[1].
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates two receptors at the same time: GLP-1 and GIP (glucose-dependent insulinotropic peptide). Because tirzepatide engages an additional biological pathway, it requires a different dose range to be effective. Its dose range is 2.5mg to 15mg per week[2].
These dose ranges are not comparable on a milligram-per-milligram basis. Tirzepatide is not “stronger” because its numbers are higher. They are higher because the medication works differently. A 5mg dose of tirzepatide is not equivalent to a 0.5mg dose of semaglutide. Different drugs, different receptors, different thresholds. The numbers cannot be directly translated.
Escalation schedule comparison
Both medications follow a structured dose escalation schedule, covered step by step in our GLP-1 dosing reference. You start at a low dose to allow your body to adjust, then increase every 4 weeks if tolerability allows. This approach reduces side effects and helps the prescriber find the dose that works for you.
| Escalation Stage | Semaglutide | Tirzepatide | Duration at each stage |
|---|---|---|---|
| Starting dose | 0.25mg | 2.5mg | 4 weeks |
| Stage 2 | 0.5mg | 5mg | 4 weeks |
| Stage 3 | 1mg | 7.5mg | 4 weeks |
| Stage 4 | 1.7mg | 10mg | 4 weeks |
| Stage 5 | 2.4mg | 12.5mg | 4 weeks |
| Maximum | 7.2mg (2.4mg is the usual maintenance dose) | 15mg | Ongoing |
Both follow a parallel structure: start low, step up every 4 weeks, reach a therapeutic plateau. Semaglutide reaches its usual 2.4mg maintenance dose in approximately 16 weeks; the current label allows some people to increase further, to a maximum of 7.2mg. Tirzepatide reaches its maximum in approximately 20 weeks. Not everyone escalates all the way. The prescriber adjusts based on your response, side effects, and goals.
Clinical trial weight loss outcomes
The real difference shows up in the clinical trials. Both medications have been studied extensively in adults with overweight or obesity. Here is what the research shows.
Semaglutide: The STEP 1 trial (published in the New England Journal of Medicine in 2021) followed 1,961 adults on either semaglutide 2.4mg or placebo for 68 weeks[3]. The semaglutide group achieved a mean weight reduction of 14.9% from baseline. This was a significant result and led to the FDA approval of branded semaglutide for chronic weight management.
Tirzepatide: The SURMOUNT-1 trial (published in the New England Journal of Medicine in 2022) randomized 2,539 adults with obesity, or overweight with at least one weight-related condition, to tirzepatide 5mg, 10mg, or 15mg or placebo for 72 weeks[2]. Mean weight reduction from baseline was 15.0% at 5mg, 19.5% at 10mg, and 20.9% at 15mg. STEP 1 and SURMOUNT-1 were separate trials with different populations and durations, so their numbers are not a direct comparison.
Head-to-head comparison: SURMOUNT-5, an open-label phase 3b trial published in 2025, randomized 751 adults with obesity without type 2 diabetes to the maximum tolerated weekly dose of tirzepatide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg) for 72 weeks[4]. Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide. The trial was funded by Eli Lilly, the manufacturer of tirzepatide. Both groups lost weight on average; the tirzepatide group lost more.
These are trial averages. Individual results vary significantly. Some people respond better to semaglutide. Some plateau at an earlier dose. Some experience side effects that limit escalation, and the two medications differ somewhat in how often those show up. A licensed provider considers your health history, prior medication experience, tolerability, and goals when choosing between these medications. For the broader picture, see our GLP-1 medication comparisons.
Compounded dosing: How to find your unit calculations
If you are taking a compounded version of either medication, you need to know your vial’s concentration. Concentrations vary by pharmacy. Common ones are semaglutide at 2.5mg/mL or 5mg/mL and tirzepatide at 5mg/mL or 10mg/mL, but check your vial label. Your vial concentration determines how many units you draw on your syringe for each prescribed dose.
For compounded semaglutide unit reference tables, see the compounded semaglutide dosage chart.
For compounded tirzepatide unit reference tables, see the compounded tirzepatide dosage chart.
Both pages include full reference tables for common concentrations, calculation methods, and safety checks before injecting. Always verify your vial concentration before drawing any dose.
How your provider decides which medication fits you
The choice between tirzepatide and semaglutide is a medical decision, not a one-size-fits-all answer. Your provider considers:
- Your weight, BMI, and weight loss goals
- Whether you have type 2 diabetes or prediabetes
- Your cardiovascular health and any history of heart disease, stroke, or high blood pressure
- Your tolerance for gastrointestinal side effects like nausea
- Whether you have tried GLP-1 medications before and how you responded
- Your family history of thyroid disease (both medications carry a warning about thyroid C-cell tumors in animal studies, though no confirmed link in humans)
- Your access to reliable refrigeration and ability to self-inject
- Cost and insurance coverage status
Both medications require you to start at the starting dose and escalate gradually. You cannot skip ahead or dose-jump. The same rule applies if you move between them, whether you follow the standard tirzepatide schedule or switch from semaglutide to a lower dose of tirzepatide. Both are prescribed only when a licensed provider determines the medication is medically appropriate for your individual health profile.
Which program is right for you
Programs that prescribe tirzepatide or semaglutide differ in ways that matter more than the name of the medication. Before you sign up anywhere, it helps to ask the same questions of each one. Our guide to which GLP-1 program fits your situation walks through the main types.
- Is the prescriber licensed in your state? At most telehealth programs, a licensed provider (a physician, nurse practitioner, or physician assistant) decides whether a prescription is appropriate. You can look up their license with your state board.
- Is the product brand-name or compounded? Brand-name products are FDA-approved. If the product is compounded, ask which state-licensed pharmacy fills it and whether it is a 503A or 503B pharmacy.
- What is the monthly cost at each dose step? Many programs price by dose, so the cost can rise as you escalate. Ask for the price at the starting dose and at the dose you may end up on.
- What does the price include? Ask whether provider visits, labs, and supplies are included, and what costs extra.
- What are the cancellation and refund terms? Find out how to cancel, how much notice is required, and whether any fees apply.
- How are dose changes and side effects handled between visits? Ask who you contact if nausea or other side effects make it hard to stay on schedule.
- Does a switch restart at the starting dose? If you move from semaglutide to tirzepatide, or the other way, expect to restart at the starting dose of the new medication.
For typical price ranges and what to ask, see the compounded semaglutide cost and compounded tirzepatide cost pages.
Transformation Health does not accept payment from providers. How we make money.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] FDA. Wegovy (semaglutide) injection and tablets prescribing information (NDA 215256). U.S. Food and Drug Administration. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[2] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
[3] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
[4] Aronne LJ, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” New England Journal of Medicine. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication. Dosing information on this page is provided as a reference only. Follow the instructions from your prescribing provider and your pharmacy label. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as FDA-approved brand-name products and may differ in formulation, purity, and potency. Clinical trial data referenced on this page (STEP 1, SURMOUNT-1, SURMOUNT-5) applies to the FDA-approved formulations studied under specific trial conditions. Results vary. Trial results describe study participants and are not a prediction for any individual. Transformation Health does not accept payment from providers. How we make money.